1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
64604B278B174A94A0025867A003B3F56
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-gathering-distributing-insights-within-medical-affairs-structure-disseminating-lessons-learned?OpenDocument
18
19OpenDocument
203.226.72.118
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Communication

Gathering and Distributing Insights within Medical Affairs: Structure, Disseminating Insights, and Lessons Learned

ID: 5666


Features:

22 Info Graphics

34 Data Graphics

640+ Metrics

15 Narratives


Pages/Slides: 67


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Gathering and Distributing Insights within Medical Affairs: Structure, Disseminating Insights, and Lessons Learned”

STUDY OVERVIEW

It is important for organizations to have a clear approach for gathering and disseminating Medical Insights that can help inform overall Medical Affairs strategies and plans. However, many Medical Affairs leaders face challenges incorporating stronger and faster Insights and Intelligence skills into the Medical Affairs workstream.

Best Practices, LLC undertook this benchmarking research to identify the best practices for gathering and distributing insights within the Medical Affairs organization. The study delivers benchmarks around the structure of Medical Insights and Dissemination groups; actionable intelligence gathering; and activities and tools required for disseminating insights. It also highlights the innovative practices and key lessons learned in effectively gathering and disseminating insights.

Benchmark data in the study is broken down into three different segments to provide deeper insights. Classifications reflect their approach and standing on Medical insight generation: Insight Leaders (17 respondents), Insight Majority (56 respondents), and Insight Laggards (11 respondents).

KEY TOPICS

  • Structure of Medical Insights and Dissemination Group
  • Disseminating Insights: Tools, Activities and Effectiveness
  • Innovative and Best Practices
  • Actionable Insights and Intelligence Gathering
  • Key Lessons Learned

KEY METRICS
  • Is there a separate group that gathers and disseminates insights for Medical Affairs?
  • What is the role of each of the groups within Medical Affairs for both gathering and disseminating insights?
  • What is the level of expertise of the person who is responsible for conveying Medical insights to other functions?
  • Please describe the strengths and weakness of your current insights gathering and dissemination group structure
  • Approximately what percentage of your intelligence deliverables falls within each of the listed categories?
  • Which of the listed tools does your Medical team use to deliver insights with other functions?
  • How effective are the listed digital tools used by your Medical Affairs team to gather, evaluate, and disseminate intelligence?
  • What additional ways does your Medical Affairs team gather intelligence (apart from KOL and HCP engagement)?

SAMPLE KEY FINDINGS
  • Medical Affairs Insight Leadership: Most companies lean on Field Teams and Medical Strategy to lead the Insight process. However, leading organizations also have thought-leader management and operations step in as well.

METHODOLOGY

Best Practices, LLC engaged 84 executives from 57 leading life sciences companies in this research. The study insights are mostly from directors and higher management executives, representing nearly 80% of the benchmark participants.

Industries Profiled:
Pharmaceutical; Biotech; Biopharmaceutical; Communications; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Chemical; Clinical Research; Laboratories; Science


Companies Profiled:
AbbVie; Adamas Pharmaceuticals; Agios Pharmaceuticals; Alcon Laboratories; ALK Abelló; Alkermes; Amgen Inc.; Amicus Therapeutics; Apellis Pharmaceuticals; ApotheCom; AstraZeneca; B. Braun Medical Inc.; Bayer; Becton Dickinson; Biohaven Pharmaceuticals; bioMerieux; Boehringer Ingelheim; Clovis Oncology; CSL Behring; Daiichi Sankyo; Eisai; Eli Lilly and Company; EMD Serono; Fidia Pharma USA Inc.; Genentech; Getinge; GlaxoSmithKline; Ipsen; Janssen Pharmaceuticals Inc.; LEO; Lundbeck; Lupin Limited; Mallinckrodt Pharmaceuticals; Merck ; Merck KGaA; Merz Pharmaceuticals; Mesoblast; Novartis; Novo Nordisk; Nutricia; Orchard Therapeutics; Pfizer; Roche; SAGE Therapeutics; Sandoz Inc.; Sanofi; Sanofi Genzyme; Sanofi Pasteur; Santen; Servier; Sunovion; Takeda; TerumoBCT; Teva Pharmaceuticals; Thermo Fisher Scientific; Vertex Pharmaceuticals; ViiV Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.